Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 23777452)

1.

18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study.

Ibrahim SF, Ahronowitz I, McCalmont TH, Hernandez Pampaloni M, Ryan JL, Yu SS.

Dermatol Surg. 2013 Sep;39(9):1323-33. doi: 10.1111/dsu.12246. Epub 2013 Jun 18.

PMID:
23777452
2.

The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.

Concannon R, Larcos GS, Veness M.

J Am Acad Dermatol. 2010 Jan;62(1):76-84. doi: 10.1016/j.jaad.2009.06.021.

PMID:
20082888
3.

Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?

Iagaru A, Quon A, McDougall IR, Gambhir SS.

Mol Imaging Biol. 2006 Jul-Aug;8(4):212-7.

PMID:
16724293
4.

18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience.

Siva S, Byrne K, Seel M, Bressel M, Jacobs D, Callahan J, Laing J, Macmanus MP, Hicks RJ.

J Nucl Med. 2013 Aug;54(8):1223-9. doi: 10.2967/jnumed.112.116814. Epub 2013 Jun 10.

5.

Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center.

Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC.

J Am Acad Dermatol. 2013 Apr;68(4):592-9. doi: 10.1016/j.jaad.2012.08.042. Epub 2012 Nov 3.

PMID:
23127473
6.

Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance.

Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM.

Am J Clin Oncol. 2005 Apr;28(2):205-10.

PMID:
15803018
7.

The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.

George A, Girault S, Testard A, Delva R, Soulié P, Couturier OF, Morel O.

Nucl Med Commun. 2014 Mar;35(3):282-90. doi: 10.1097/MNM.0000000000000039.

PMID:
24240193
8.

Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients.

Maury G, Dereure O, Du-Thanh A, Mariano-Goulart D, Guillot B.

J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1420-7. doi: 10.1111/j.1468-3083.2011.03994.x. Epub 2011 Mar 2.

PMID:
21366705
9.

18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.

Kumar R, Xiu Y, Zhuang HM, Alavi A.

Br J Dermatol. 2006 Aug;155(2):357-63.

PMID:
16882175
10.
11.

Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma.

Epstude M, Tornquist K, Riklin C, di Lenardo F, Winterhalder R, Hug U, Strobel K.

Clin Nucl Med. 2013 Apr;38(4):283-4. doi: 10.1097/RLU.0b013e318281658e.

PMID:
23429397
12.

Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.

Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, Schuller DE.

Laryngoscope. 2007 Jul;117(7):1173-9.

PMID:
17603315
13.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
14.

Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.

Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, Iguchi H.

Pancreas. 2013 Jan;42(1):11-9. doi: 10.1097/MPA.0b013e3182550d77.

PMID:
22699206
15.

Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma.

Lu Y, Fleming SE, Fields RC, Coit DG, Carrasquillo JA.

Clin Nucl Med. 2012 Aug;37(8):759-62. doi: 10.1097/RLU.0b013e31825ae8e7.

PMID:
22785503
16.

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.

Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N.

BMC Cancer. 2010 Dec 3;10:667. doi: 10.1186/1471-2407-10-667.

17.

Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.

Povoski SP, Hall NC, Murrey DA Jr, Chow AZ, Gaglani JR, Bahnson EE, Mojzisik CM, Kuhrt MP, Hitchcock CL, Knopp MV, Martin EW Jr.

World J Surg Oncol. 2011 Nov 23;9:152. doi: 10.1186/1477-7819-9-152.

18.

Role of nuclear medicine in staging and management in a case of Merkel cell carcinoma.

Ochoa-Figueroa MA, Uña-Gorospe J, Allende-Riera A, Muñoz-Iglesias J, Cárdenas-Negro C, González-Delgado B.

Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):354-6. doi: 10.1016/j.remn.2011.10.008. Epub 2011 Dec 15. English, Spanish. No abstract available.

19.
20.

Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.

Kalff V, Hicks RJ, Ware RE, Greer B, Binns DS, Hogg A.

Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15. Epub 2002 Feb 15.

PMID:
11914889
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk